145 related articles for article (PubMed ID: 15368520)
21. Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment.
Sarin SK; Kumar M; Hissar S; Sharma BC
Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):374-80. PubMed ID: 16911934
[TBL] [Abstract][Full Text] [Related]
22. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.
Horiike N; Fazle Akbar SM; Michitaka K; Joukou K; Yamamoto K; Kojima N; Hiasa Y; Abe M; Onji M
J Clin Virol; 2005 Feb; 32(2):156-61. PubMed ID: 15653419
[TBL] [Abstract][Full Text] [Related]
23. [Hepatitis B core antigen expression pattern predicts response to lamivudine therapy in patients with chronic hepatitis B].
Shi KD; Hwang SG; Choi JH; Hwang IJ; Yoon JH; Kim KI; Kwon CI; Hong SP; Park PW; Rim KS
Korean J Hepatol; 2008 Jun; 14(2):197-205. PubMed ID: 18617767
[TBL] [Abstract][Full Text] [Related]
24. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
25. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
Sarin SK; Sandhu BS; Sharma BC; Jain M; Singh J; Malhotra V
J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556
[TBL] [Abstract][Full Text] [Related]
26. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I
Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688
[TBL] [Abstract][Full Text] [Related]
27. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy.
Kim JH; Yu SK; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Lee CH; Byun KS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1220-5. PubMed ID: 17532786
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis B core antigen expression pattern reflects the response to anti-viral treatment.
Uzun Y; Bozkaya H; Erden E; Cinar K; Idilman R; Yurdaydin C; Uzunalimoglu O
J Gastroenterol Hepatol; 2006 Jun; 21(6):977-81. PubMed ID: 16724981
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
[TBL] [Abstract][Full Text] [Related]
31. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
Manolakopoulos S; Bethanis S; Elefsiniotis J; Karatapanis S; Triantos C; Sourvinos G; Touloumi G; Economou M; Vlachogiannakos J; Spandidos D; Avgerinos A; Tzourmakliotis D
Aliment Pharmacol Ther; 2006 Mar; 23(6):787-95. PubMed ID: 16556181
[TBL] [Abstract][Full Text] [Related]
32. [Construction of HLA-A2-peptide tetramer and application in HBV/HCV infection].
Piao WH; He Y; Xi HL; Sun XT; Zhang HH; Xu JH; Zhao H; Xu WX; Li ZL; Wang GQ
Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(21):1818-22. PubMed ID: 15631781
[TBL] [Abstract][Full Text] [Related]
33. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
[TBL] [Abstract][Full Text] [Related]
34. Vigorous response of cytotoxic T lymphocytes associated with systemic activation of CD8 T lymphocytes in fulminant hepatitis B.
Kondo Y; Kobayashi K; Asabe S; Shiina M; Niitsuma H; Ueno Y; Kobayashi T; Shimosegawa T
Liver Int; 2004 Dec; 24(6):561-7. PubMed ID: 15566505
[TBL] [Abstract][Full Text] [Related]
35. Effects of HBV gene variations on disease development and antiviral therapy for patients with chronic hepatitis B.
Chen JY; Wang LW; Sun XM; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):393-7. PubMed ID: 16109523
[TBL] [Abstract][Full Text] [Related]
36. [Clinical profiles of circulating dendritic cell phenotype and lymphocyte subsets in patients chronically infected with HBV during lamivudine treatment].
Li HW; Wang HF; Wang FS; Jin B; Duan XZ
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Mar; 20(1):43-6. PubMed ID: 16642218
[TBL] [Abstract][Full Text] [Related]
37. Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients.
Wang Y; Takao Y; Harada M; Komatsu N; Ono T; Sata M; Itoh K; Yamada A
Cell Immunol; 2006 May; 241(1):38-46. PubMed ID: 16963008
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B virus (HBV) core antigen-specific regulatory T cells confer sustained remission to anti-HBV therapy in chronic hepatitis B with acute exacerbation.
Koay LB; Feng IC; Sheu MJ; Kuo HT; Lin CY; Chen JJ; Wang SL; Tang LY; Tsai SL
Hum Immunol; 2011 Sep; 72(9):687-98. PubMed ID: 21215784
[TBL] [Abstract][Full Text] [Related]
39. Induction of oral immune regulation towards liver-extracted proteins for treatment of chronic HBV and HCV hepatitis: results of a phase I clinical trial.
Israeli E; Safadi R; Melhem A; Pappo O; Shibolet O; Klein A; Hemed N; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Liver Int; 2004 Aug; 24(4):295-307. PubMed ID: 15287852
[TBL] [Abstract][Full Text] [Related]
40. Virus-specific T cell immune response in children and adolescents with chronic hepatitis B virus infection.
Fischler B; Nyström J; Björnsdottir T; Lindh G; Hultgren C
J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):75-83. PubMed ID: 17592368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
